688076 ST诺泰
已收盘 07-20 15:00:01
资讯
新帖
简况
股市必读：ST诺泰（688076）新发布《中喜会计师事务所（特殊普通合伙）关于江苏诺泰澳赛诺生物制药股份有限公司2025年年度报告及2026年第一季度报告的信息披露监管问询函有关财务问题的回复》
证券之星 · 07-13
股市必读：ST诺泰（688076）新发布《中喜会计师事务所（特殊普通合伙）关于江苏诺泰澳赛诺生物制药股份有限公司2025年年度报告及2026年第一季度报告的信息披露监管问询函有关财务问题的回复》
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告，7月8日股价下跌0.91%
证券之星 · 07-08
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告，7月8日股价下跌0.91%
每周股票复盘：ST诺泰（688076）第三期限制性股票归属76.4万股
证券之星 · 06-28
每周股票复盘：ST诺泰（688076）第三期限制性股票归属76.4万股
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期符合归属条件的公告，6月26日股价下跌1.72%
证券之星 · 06-26
ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期符合归属条件的公告，6月26日股价下跌1.72%
ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段
证券之星 · 06-03
ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段
ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系
证券之星 · 06-03
ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系
每周股票复盘：ST诺泰（688076）2025年年度股东会顺利召开
证券之星 · 05-31
每周股票复盘：ST诺泰（688076）2025年年度股东会顺利召开
股市必读：ST诺泰（688076）今年截至5月28日累计跌幅已超25%
证券之星 · 05-29
股市必读：ST诺泰（688076）今年截至5月28日累计跌幅已超25%
每周股票复盘：ST诺泰（688076）2025年净利3.32亿拟每股分红0.35元
证券之星 · 05-24
每周股票复盘：ST诺泰（688076）2025年净利3.32亿拟每股分红0.35元
ST诺泰（688076）披露控股股东、实际控制人续签一致行动协议公告，5月21日股价下跌1.23%
证券之星 · 05-21
ST诺泰（688076）披露控股股东、实际控制人续签一致行动协议公告，5月21日股价下跌1.23%
ST诺泰（688076）披露2025年年度股东会会议资料，5月18日股价下跌0.99%
证券之星 · 05-18
ST诺泰（688076）披露2025年年度股东会会议资料，5月18日股价下跌0.99%
每周股票复盘：ST诺泰（688076）2026Q1营收略降扣非净利下滑17.78%
证券之星 · 05-17
每周股票复盘：ST诺泰（688076）2026Q1营收略降扣非净利下滑17.78%
股市必读：ST诺泰（688076）5月14日披露最新机构调研信息
证券之星 · 05-15
股市必读：ST诺泰（688076）5月14日披露最新机构调研信息
每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%
证券之星 · 05-10
每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%
ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%
证券之星 · 05-08
ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%
ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%
证券之星 · 04-30
ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%
图解ST诺泰年报：第四季度单季净利润同比下降307.09%
证券之星 · 04-30
图解ST诺泰年报：第四季度单季净利润同比下降307.09%
每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿
证券之星 · 04-12
每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿
ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%
中金财经 · 04-07
ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%
股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%
证券之星 · 03-24
股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%
加载更多
公司概况
公司名称：
江苏诺泰澳赛诺生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2021-05-20
主营业务：
江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是定制类产品、技术服务、自主选择产品。
发行价格：
15.57
{"stockData":{"symbol":"688076","market":"SH","secType":"STK","nameCN":"ST诺泰","latestPrice":27.71,"timestamp":1784530801000,"preClose":28,"halted":0,"volume":2697125,"delay":0,"changeRate":-0.0104,"floatShares":317000000,"shares":317000000,"eps":0.9762,"marketStatus":"已收盘","change":-0.29,"latestTime":"07-20 15:00:01","open":27.95,"high":28.25,"low":27.11,"amount":74805900,"amplitude":0.0407,"askPrice":27.71,"askSize":2,"bidPrice":27.68,"bidSize":10,"shortable":0,"etf":0,"ttmEps":0.9762,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784597400000},"marketStatusCode":5,"adr":0,"adjPreClose":28,"symbolType":"stock_kcb","openAndCloseTimeList":[[1784511000000,1784518200000],[1784523600000,1784530800000]],"highLimit":29.4,"lowLimit":26.6,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":316815961,"isCdr":false,"pbRate":2.82,"roa":"--","peRate":28.385577,"roe":"4.24%","epsLYR":1.06,"committee":-0.152104,"marketValue":8779000000,"turnoverRate":0.0085,"status":1,"afterMarket":{"amount":59881.31,"volume":2161,"close":27.71,"buyVolume":0,"sellVolume":2639,"time":1784532837746,"indexStatus":"已收盘 07-20 15:30:00","preClose":28},"floatMarketCap":8779000000},"requestUrl":"/m/hq/s/688076","defaultTab":"news","newsList":[{"id":"2651166308","title":"股市必读：ST诺泰（688076）新发布《中喜会计师事务所（特殊普通合伙）关于江苏诺泰澳赛诺生物制药股份有限公司2025年年度报告及2026年第一季度报告的信息披露监管问询函有关财务问题的回复》","url":"https://stock-news.laohu8.com/highlight/detail?id=2651166308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651166308?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:12","pubTimestamp":1783879932,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，ST诺泰报收于28.54元，上涨0.85%，换手率0.84%，成交量2.65万手，成交额7590.9万元。公司公告汇总：ST诺泰就上交所关于2025年年报及2026年一季报的信息披露监管问询函作出回复，年审会计师确认收入确认真实准确、资产减值准备计提充分。公司公告汇总：中喜会计师事务所就财务相关问询出具专项回复，披露公司2025年营收19.43亿元、归母净利润3.32亿元，2026年一季度净利润1.29亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649994140","title":"ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告，7月8日股价下跌0.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649994140","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649994140?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:37","pubTimestamp":1783521434,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘，ST诺泰报收于28.45元，较前一交易日下跌0.91%，最新总市值为89.92亿元。近日，ST诺泰发布《关于2023年限制性股票激励计划第三个归属期归属结果暨股份上市公告》。公告显示，公司完成2023年限制性股票激励计划第三个归属期的股份归属登记，本次归属股份数量为764,064股，来源为公司向激励对象定向发行A股普通股股票，归属对象共58人，包括董事、高级管理人员、核心技术人员及其他激励对象。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800043033.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646931574","title":"每周股票复盘：ST诺泰（688076）第三期限制性股票归属76.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646931574","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646931574?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:52","pubTimestamp":1782589932,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，ST诺泰报收于26.25元，较上周的27.43元下跌4.3%。本周，ST诺泰6月23日盘中最高价报28.75元。ST诺泰当前最新总市值82.96亿元，在化学制药板块市值排名54/150，在两市A股市值排名2188/5206。本周关注点公司公告汇总：ST诺泰第三期限制性股票归属76.4064万股，58人符合归属条件。本次可归属数量为76.4064万股，归属人数为58人，股票来源为公司向激励对象定向发行A股普通股。本次合计作废处理限制性股票5.768万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800001220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646366369","title":"ST诺泰（688076）披露2023年限制性股票激励计划第三个归属期符合归属条件的公告，6月26日股价下跌1.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366369","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646366369?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:58","pubTimestamp":1782485898,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，ST诺泰报收于26.25元，较前一交易日下跌1.72%，最新总市值为82.96亿元。该股当日开盘26.7元，最高27.49元，最低26.19元，成交额达5156.86万元，换手率为0.62%。近日，ST诺泰发布《关于公司2023年限制性股票激励计划第三个归属期符合归属条件的公告》。公司层面业绩考核达标，2025年营业收入增长率达198.30%，满足第三个归属期目标值要求，公司层面归属比例为100%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600046131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640972060","title":"ST诺泰：公司自主研发的英克司兰注射液目前处于小试阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2640972060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640972060?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475256,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有英克司兰原料药的技术，建议公司开发相当于英克司兰的长效降脂药物品种，在小核酸方向主攻研发创新药，加大研发。祝公司越来越好。ST诺泰回复：尊敬的投资者您好，公司自主研发的英克司兰注射液目前处于小试阶段，具体您可查阅公司2025年年度报告-在研项目情况，感谢您的关注与建议！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033193.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640722199","title":"ST诺泰：已与Incyte、Gilead等知名创新药企建立稳固合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2640722199","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640722199?lang=zh_cn&edition=full","pubTime":"2026-06-03 16:27","pubTimestamp":1780475250,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰(688076)06月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好 近日看到信达与辉瑞签订超100亿美元的肿瘤药物研发合同，我想请问诺泰生物何时能具备与国际大厂签订药物研发计划的能力？ST诺泰回复：尊敬的投资者您好，公司已与Incyte、Gilead等知名创新药企建立了稳固的合作关系，公司会在定期报告中披露已签署重要订单情况。此外，公司如签订达到《上海证券交易所科创板股票上市规则》中规定的重大合同披露标准的订单合同，会及时履行信息披露义务，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060300033187.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","159992","06978","BK0239","BK1161","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604120","title":"每周股票复盘：ST诺泰（688076）2025年年度股东会顺利召开","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604120?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:39","pubTimestamp":1780169949,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，ST诺泰报收于29.84元，较上周的30.53元下跌2.26%。本周关注点公司公告汇总：ST诺泰2025年年度股东会于2026年5月26日召开，审议通过多项议案，表决程序合法有效。江苏诺泰澳赛诺生物制药股份有限公司于2026年5月26日召开2025年年度股东会，会议由董事会召集，董事长童梓权主持，采用现场与网络投票结合方式表决。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639618903","title":"股市必读：ST诺泰（688076）今年截至5月28日累计跌幅已超25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639618903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639618903?lang=zh_cn&edition=full","pubTime":"2026-05-29 02:10","pubTimestamp":1779991824,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，ST诺泰报收于29.69元，下跌0.13%，换手率0.58%，成交量1.83万手，成交额5388.66万元。当日关注点来自交易信息汇总：ST诺泰股价连续5日下跌，2026年累计跌幅达26.58%。交易信息汇总股价提醒5月28日ST诺泰收盘报29.69元，跌0.13%，当日成交182.77万元。前10个交易日中，主力资金累计净流出8579.97万元，股价累计下跌5.52%；融资余额累计减少2458.33万元，融券余量累计增加1300股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900001990.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637375857","title":"每周股票复盘：ST诺泰（688076）2025年净利3.32亿拟每股分红0.35元","url":"https://stock-news.laohu8.com/highlight/detail?id=2637375857","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637375857?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:18","pubTimestamp":1779563892,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，ST诺泰报收于30.53元，较上周的31.29元下跌2.43%。本周，ST诺泰5月19日盘中最高价报31.66元。2025年公司实现营业收入19.43亿元，同比增长19.57%；归属于母公司所有者的净利润3.32亿元。ST诺泰：关于公司控股股东、实际控制人续签一致行动协议的公告江苏诺泰澳赛诺生物制药股份有限公司控股股东、实际控制人赵德毅、赵德中于2026年5月20日续签《一致行动协议》，新协议有效期自签署之日起一年，至2027年5月19日止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138422","title":"ST诺泰（688076）披露控股股东、实际控制人续签一致行动协议公告，5月21日股价下跌1.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138422","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138422?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:09","pubTimestamp":1779358157,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，ST诺泰报收于30.55元，较前一交易日下跌1.23%，最新总市值为96.55亿元。公司于近日披露《关于公司控股股东、实际控制人续签一致行动协议的公告》。公告显示，江苏诺泰澳赛诺生物制药股份有限公司控股股东、实际控制人赵德毅、赵德中于2026年5月20日续签《一致行动协议》，新协议有效期自签署之日起一年，至2027年5月19日止。本次续签不影响公司实际控制权，控制权未发生变更。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636074510","title":"ST诺泰（688076）披露2025年年度股东会会议资料，5月18日股价下跌0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636074510","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636074510?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:24","pubTimestamp":1779114263,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，ST诺泰报收于30.98元，较前一交易日下跌0.99%，最新总市值为97.91亿元。该股当日开盘31.37元，最高31.37元，最低30.75元，成交额达5730.42万元，换手率为0.59%。近日，ST诺泰发布《2025年年度股东会会议资料》。2025年公司实现营业收入19.43亿元，同比增长19.57%；归属于母公司所有者的净利润3.32亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636064596","title":"每周股票复盘：ST诺泰（688076）2026Q1营收略降扣非净利下滑17.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636064596","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636064596?lang=zh_cn&edition=full","pubTime":"2026-05-17 03:12","pubTimestamp":1778958731,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，ST诺泰报收于31.29元，较上周的32.1元下跌2.52%。本周，ST诺泰5月12日盘中最高价报33.28元。本周关注点来自业绩披露要点：2025年归母净利润下滑17.8%，主要受资产减值、证监会罚款及财务费用上升影响。2026年Q1营收同比略降主要因流感季节性影响，抗病毒制剂销售额下降；部分产品受行业价格波动影响毛利率下滑，拖累净利润。2026Q1营收下降系流感季节性波动所致，非价跌量升；抗病毒制剂销售收入同比下降为主要原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700000947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635574787","title":"股市必读：ST诺泰（688076）5月14日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2635574787","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635574787?lang=zh_cn&edition=full","pubTime":"2026-05-15 02:02","pubTimestamp":1778781738,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，ST诺泰报收于31.45元，下跌2.39%，换手率0.96%，成交量3.04万手，成交额9637.67万元。来自机构调研要点：司美格鲁肽、替尔泊肽、利拉鲁肽三个GLP-1原料药2025年出货量同比大幅增长。2026年Q1营收同比下降主要因流感季节性影响，抗病毒制剂产品销售下滑；部分产品受行业价格波动影响，毛利率同比下降。公司力争2026年度营业收入较上年保持稳定增长，该预算不代表盈利预测，亦不构成对股东的承诺，存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634411497","title":"每周股票复盘：ST诺泰（688076）收4740万罚单且净利降17.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634411497","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634411497?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:44","pubTimestamp":1778348653,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，ST诺泰报收于32.1元，较上周的29.73元上涨7.97%。本周，ST诺泰5月8日盘中最高价报32.2元。本周关注点公司公告汇总：公司被证监会罚款4,740万元，多名高管被警告并处罚。公司公告汇总南京证券作为江苏诺泰澳赛诺生物制药股份有限公司的保荐机构，出具2025年度持续督导报告书。2025年公司营业收入同比增长19.57%，净利润同比下降17.80%，研发投入占比上升至23.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000402.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633034452","title":"ST诺泰（688076）披露2025年度持续督导报告书，5月8日股价上涨7.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633034452","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633034452?lang=zh_cn&edition=full","pubTime":"2026-05-08 22:12","pubTimestamp":1778249543,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，ST诺泰报收于32.1元，较前一交易日上涨7.18%，最新总市值为101.45亿元。该股当日开盘30.11元，最高32.2元，最低29.95元，成交额达2.15亿元，换手率为2.16%。近日，南京证券股份有限公司作为江苏诺泰澳赛诺生物制药股份有限公司的保荐机构，发布《关于江苏诺泰澳赛诺生物制药股份有限公司2025年度持续督导报告书》。保荐机构督促公司整改，强化公司治理与内部控制。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800043603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631687610","title":"ST诺泰（688076）披露2025年年度报告，4月30日股价上涨1.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631687610","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631687610?lang=zh_cn&edition=full","pubTime":"2026-04-30 18:07","pubTimestamp":1777543635,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，ST诺泰报收于29.73元，较前一交易日上涨1.75%，最新总市值为93.96亿元。该股当日开盘29.59元，最高29.99元，最低29.58元，成交额达6137.48万元，换手率为0.65%。公司于2026年4月30日披露《2025年年度报告》。报告显示，2025年公司总资产6,740,348,583.14元，归属于上市公司股东的净资产2,985,566,515.25元，营业收入1,942,799,144.82元，利润总额360,489,776.54元，归属于上市公司股东的净利润332,418,681.18元，归属于上市公司股东的扣除非经常性损益的净利润366,170,169.99元，经营活动产生的现金流量净额681,242,898.86元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000058548.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631442475","title":"图解ST诺泰年报：第四季度单季净利润同比下降307.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631442475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631442475?lang=zh_cn&edition=full","pubTime":"2026-04-30 00:55","pubTimestamp":1777481715,"startTime":"0","endTime":"0","summary":"证券之星消息，ST诺泰2025年年报显示，当年度公司主营收入19.43亿元，同比上升19.57%；归母净利润3.32亿元，同比下降17.8%；扣非净利润3.66亿元，同比下降10.21%；其中2025年第四季度，公司单季度主营收入4.16亿元，同比上升11.56%；单季度归母净利润-1.12亿元，同比下降307.09%；单季度扣非净利润-7081.72万元，同比下降233.27%；负债率55.47%，投资收益202.56万元，财务费用5781.34万元，毛利率62.64%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000002938.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626212471","title":"每周股票复盘：ST诺泰（688076）预计一季度净利1.2亿至1.4亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2626212471","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626212471?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:28","pubTimestamp":1775928489,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，ST诺泰报收于30.7元，较上周的29.02元上涨5.79%。本周，ST诺泰4月10日盘中最高价报31.1元。本周关注点业绩披露要点：ST诺泰预计2026年一季度扣非及归属净利润均为1.2亿元至1.4亿元。公司公告汇总：ST诺泰称一季度净利润同比减少8.27%至21.37%，主因部分产品毛利率下降。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625374499","title":"ST诺泰(688076.SH)：一季度净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625374499","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625374499?lang=zh_cn&edition=full","pubTime":"2026-04-07 19:37","pubTimestamp":1775561822,"startTime":"0","endTime":"0","summary":"格隆汇4月7日丨ST诺泰(688076.SH)发布一季度业绩预告，预计一季度归属于上市公司股东的净利润为1.20亿元—1.40亿元，同比预减8.27%—21.37%；预计一季度归属于上市公司股东的扣除非经常性损益的净利润为1.20亿元—1.40亿元，同比预减7.65%—20.84%，报告期内，公司部分销售产品受行业价格波动影响，毛利率水平同比下降。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260407/32128790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688076"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621089903","title":"股市必读：ST诺泰（688076）今年截至3月23日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621089903","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621089903?lang=zh_cn&edition=full","pubTime":"2026-03-24 03:19","pubTimestamp":1774293592,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，ST诺泰报收于28.61元，下跌5.58%，换手率1.29%，成交量4.07万手，成交额1.19亿元。来自交易信息汇总：该股当年累计跌幅达23.57%，前10个交易日主力资金累计净流出1.3亿元。交易信息汇总股价提醒3月23日ST诺泰收盘报28.61元，跌5.58%，当日成交407.11万元。根据收盘数据统计，该股已连续4日下跌，当年累计跌幅23.57%。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688076"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784581015845,"stockEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0678},{"period":"6month","weight":-0.2501},{"period":"1year","weight":-0.315},{"period":"ytd","weight":-0.2554}],"compareEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.0719},{"period":"3month","weight":-0.0707},{"period":"6month","weight":-0.0779},{"period":"1year","weight":0.0741},{"period":"ytd","weight":-0.0435}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"江苏诺泰澳赛诺生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15016人(较上一季度减少1.48%)","perCapita":"21098股","listingDate":"2021-05-20","address":"江苏省连云港市连云区经济技术开发区临浦路28号","registeredCapital":"31681万元","survey":" 江苏诺泰澳赛诺生物制药股份有限公司的主营业务是多肽药物及小分子化药的自主研发与定制研发生产。公司的主要产品是定制类产品、技术服务、自主选择产品。","listedPrice":15.57},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ST诺泰,688076,ST诺泰股票,ST诺泰股票老虎,ST诺泰股票老虎国际,ST诺泰行情,ST诺泰股票行情,ST诺泰股价,ST诺泰股市,ST诺泰股票价格,ST诺泰股票交易,ST诺泰股票购买,ST诺泰股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ST诺泰(688076)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ST诺泰(688076)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}